Non-Small-Cell Lung Carcinoma Clinical Trials

188 clinical trials for Non-Small-Cell Lung Carcinoma across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations — RECRUITING · PHASE1
• To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy — RECRUITING · PHASE3
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — RECRUITING · PHASE1
• Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT — RECRUITING · PHASE2
• A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) — RECRUITING · PHASE3
• First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea — RECRUITING
• Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer — RECRUITING
• A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. — RECRUITING · PHASE3
• Retifanlimab and Ruxolitinib In Solid Malignancies — RECRUITING · PHASE1
• The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors — RECRUITING
• Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection — RECRUITING · PHASE3
• Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer — SUSPENDED · PHASE1
• Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) — SUSPENDED · PHASE1
• A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC — ACTIVE_NOT_RECRUITING · PHASE1
• Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer — COMPLETED · PHASE2
• A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors — COMPLETED · PHASE1
• Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) — COMPLETED · PHASE3
• Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) — COMPLETED · PHASE3
• Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation — ACTIVE_NOT_RECRUITING · PHASE1
• NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC — TERMINATED · PHASE2
• Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor — NOT_YET_RECRUITING · PHASE2
• Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy. — NOT_YET_RECRUITING · PHASE4
• Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers — COMPLETED · NA
• Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer — COMPLETED · PHASE1
• Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment — ACTIVE_NOT_RECRUITING · NA
• Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. — COMPLETED · PHASE4
• Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery — COMPLETED · PHASE1
• Neoadjuvant Pembrolizumab — COMPLETED · PHASE2
• A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled — COMPLETED
• Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC) — COMPLETED
• A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation — TERMINATED · PHASE1
• Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy — ACTIVE_NOT_RECRUITING · PHASE1
• A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer — ACTIVE_NOT_RECRUITING · NA
• Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients — COMPLETED · NA
• Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot Study — ACTIVE_NOT_RECRUITING · NA
• DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) — NOT_YET_RECRUITING · PHASE1
• Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies — TERMINATED · PHASE1
• Study of IK-595 in RAS- or RAF-altered Advanced Tumors — TERMINATED · PHASE1
• Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer — COMPLETED · PHASE2
• ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer — COMPLETED · PHASE1
• Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma — TERMINATED · PHASE1
• Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment — COMPLETED · PHASE1
• Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) — COMPLETED · PHASE3
• Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns — COMPLETED
• A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) — COMPLETED · PHASE1
• Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study — COMPLETED · PHASE3
• Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients — COMPLETED · PHASE1

Refine this search